European CHMP recommends approval of new formulation of ravulizumab (Ultomiris)

The new 100 mg/mL formulation will reduce infusion time by approximately 60%, vs the currently available 10mg/mL IV formulation (from 77 to 194 minutes to 25 to 75 minutes, depending on body weight) thus lessening the burden on patients and health systems.


Biospace Inc.